You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Spotlight on Multiple Myeloma and AL Amyloidosis: Where Are We Today?

  • Authors: Philippe Moreau, MD​; Hermann Einsele, MD, PhD;​ Monique Minnema, MD, PhD; Paula Rodriguez Otero, MD, PhD; Giovanni Palladini, MD, PhD​
  • CPD Released: 11/30/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 11/30/2022
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically hematology/oncology specialists, cardiologists, and nephrologists.

The goal of this activity is to improve knowledge of clinical trial data on immunotherapeutic approaches for multiple myeloma (MM) and amyloid light chain (AL) amyloidosis, and improve competence and confidence in applying these data to determine an individualized course of care for patients with this disease.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest recommendations for the treatment of newly diagnosed MM
    • Latest data with CAR T-cell therapies for relapsed/refractory (R/R) MM
    • Latest data with bispecific antibodies for R/R MM
    • Latest data with novel small molecule therapies for R/R MM
    • Latest data with emerging treatment strategies for AL amyloidosis


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Disclosures for additional planners can be found here.

Predisposing statement


Faculty

  • Philippe Moreau, MD

    University Professor of Clinical Hematology ​
    Head, Hematology Department
    University Hospital of Nantes
    Nantes, France ​

    Disclosures

    Disclosure: Philippe Moreau, MD, has the following relevant financial relationships:
    Advisor or consultant for: AbbVie; Amgen; Celgene; Janssen; Oncopeptides; Sanofi

  • Hermann Einsele, MD, PhD

    Professor​
    Director of Internal Medicine
    Universitätsklinikum Würzburg​
    Würzburg, Germany

    Disclosures

    Disclosure: Hermann Einsele, MD, PhD, has disclosed the following relevant financial relationships:
    Advisor or consultant for: Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Sanofi
    Speaker or a member of a speakers bureau for: Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda
    Grants for clinical research from: Amgen; Bristol Myers Squibb Company; Celgene; Janssen

  • Monique Minnema, MD, PhD

    Professor of Hematology
    University Medical Center Utrecht
    Utrecht, The Netherlands

    Disclosures

    Disclosure: Monique Minnema, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Alnylam; Cilag; Gilead; Janssen
    Speaker or a member of a speakers bureau for: Bristol Myers Squibb Company
    Other: Celgene (hospitality)

  • Paula Rodriguez Otero, MD, PhD

    Consultant​
    Clinical Universidad de Navarra
    University of Navarra ​
    Pamplona, Spain

    Disclosures

    Disclosure: Paula Rodriguez Otero, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Oncopeptides
    Speaker or a member of a speakers bureau for: Amgen; Bristol Myers Squibb Company; Celgene; Janssen; Sanofi

  • Giovanni Palladini, MD, PhD

    Amyloidosis Research and Treatment Center​
    Fondazione IRCCS ​Policlinico San Matteo ​
    Department of Molecular Medicine ​
    University of Pavia​
    Pavia, Italy

    Disclosures

    Disclosure: Giovanni Palladini, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Janssen
    Speaker or a member of a speakers bureau for: Janssen; Pfizer; Siemens

Editor

  • Keisha Peters, MSc

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Keisha Peters, MSc, has disclosed no relevant financial relationships.

Content Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Spotlight on Multiple Myeloma and AL Amyloidosis: Where Are We Today?

Authors: Philippe Moreau, MD​; Hermann Einsele, MD, PhD;​ Monique Minnema, MD, PhD; Paula Rodriguez Otero, MD, PhD; Giovanni Palladini, MD, PhD​Faculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 11/30/2021

Valid for credit through: 11/30/2022

processing....

Select Any Chapter to Begin

Did you know that around 10% to 15% of patients with multiple myeloma (MM) develop clinical evident amyloid light chain (AL) amyloidosis, but the reverse situation is very rare (around 0.4%)?

  • Print